4 Of The Best Income Stocks Around: GlaxoSmithKline plc, Standard Life Plc, SSE PLC And Centrica plc

GlaxoSmithKline plc (LON: GSK), Standard Life Plc (LON: SL), SSE PLC (LON: SSE) and Centrica PLC (LON:CNA) are four of the best dividend plays around.

| More on:

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

When investing, your capital is at risk. The value of your investments can go down as well as up and you may get back less than you put in.

Read More

The content of this article is provided for information purposes only and is not intended to be, nor does it constitute, any form of personal advice. Investments in a currency other than sterling are exposed to currency exchange risk. Currency exchange rates are constantly changing, which may affect the value of the investment in sterling terms. You could lose money in sterling even if the stock price rises in the currency of origin. Stocks listed on overseas exchanges may be subject to additional dealing and exchange rate charges, and may have other tax implications, and may not provide the same, or any, regulatory protection as in the UK.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

Standard Life (LSE: SL) has transformed itself into an income champion over the past five years. The company’s shift to a fee-based business model has led to a tripling of cash flow generated from operations since 2010. Assets under management have risen by 50% over the same period. 

This growth has helped support the company’s dividend payout growth. Since 2011 Standard’s dividend payout has increased at a steady rate of 7% per annum. Since 2010 Standard Life has returned 147p per share to investors, including the recent special dividend and over five years the shares have produced a total return of 180%. Based on the estimated growth of the UK pension market, the next five years could see a similar performance. 

Standard Life trades at a forward P/E of 16.8 and supports a yield of 4.6%. Earnings per share are predicted to grow by 48% this year. 

Dividend concerns 

GlaxoSmithKline’s (LSE: GSK) shares have sunk to a four-year low on fears about the sustainability of the company’s dividend payout. However, to a certain extent, these concerns are unfounded.

Management has stated that the company’s dividend of 80p per share is safe for the next three years. A special dividend of 20p per share payable during the fourth quarter will take the total payout for 2015 to 100p per share, a yield of 7.9% based on Glaxo’s current share price. 

Glaxo currently trades at a forward P/E of 16.9 and supports a yield of 7.2%. Earnings per share are predicted to shrink by 21% this year. 

Slow and steady 

Last year, SSE (LSE: SSE) made a commitment to target an increase in the full-year dividend for 2015/16 of at least RPI inflation, with annual increases thereafter of at least RPI inflation also being targeted.

This is hardly the most impressive dividend policy. The RPI measure of inflation has averaged 1% this year, so investors won’t see much in the way of a dividend increase at all. 

Nevertheless, for the conservative dividend investor SSE’s dividend policy is ideal. The payout is covered 1.2 times by earnings per share and due to the nature of SSE’s business, the company has a certain degree of clarity over its revenue streams. As a result, it’s unlikely management will suddenly take an axe to the dividend. 

SSE currently trades at a forward P/E of 12.6 and supports a yield of 6.2%. Earnings per share are predicted to shrink by 10% this year.

Changing business model 

Centrica (LSE: CNA) has already cut its dividend payout once this year. However, according to City projections the new, lower payout is now covered one-and-a-half times by earnings per share, leaving plenty of room for manoeuvre. 

What’s more, management’s recent decision to scale back Centrica’s upstream business is a great move for the company. Oil & gas production is a notoriously volatile and capital intensive business. Focusing on the more predictable customer-facing side of the business should put Centrica back on the path to long-term sustainable growth.

Also, Centrica’s focus on the more predictable customer side of the business should help the company maintain and increase its dividend over time.  

Centrica currently trades at a forward P/E of 12.5 and supports a yield of 5.4%. Earnings per share are predicted to shrink by 7% this year.

Should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be assessed. Consider taking independent financial advice.

Rupert Hargreaves owns shares of GlaxoSmithKline. The Motley Fool UK has recommended Centrica and GlaxoSmithKline. We Fools don't all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors.

More on Investing Articles

Concept of two young professional men looking at a screen in a technological data centre
Investing Articles

Can the FTSE 250’s Raspberry Pi boost my portfolio over the next decade?

This British technology stock in the FTSE 250 has exploded onto the London stock market and right now its future…

Read more »

Investing Articles

Does acquiring Direct Line make Aviva shares a buy?

A big acquisition should give Aviva greater scale and profitability, increasing the value of its shares. But is it an…

Read more »

Investing Articles

After a 25% decline in 2024, this FTSE 250 stock is top of my buy list for the New Year

Stephen Wright’s top investment idea is a FTSE 250 stock that’s down 25% this year in an industry that’s under…

Read more »

The words "what's your plan for retirement" written on chalkboard on pavement somewhere in London
Retirement Articles

After a 20% gain in 2024, here’s how I’ll be investing my Stocks and Shares ISA and SIPP in 2025

Edward Sheldon is saving for retirement in a Stocks and Shares ISA and pension. Here’s how he’ll be investing in…

Read more »

Investing Articles

2 S&P 500 funds to consider for huge profits in 2025!

Are you optimistic about the S&P 500's prospects in the New Year? These quality exchange-traded funds (ETFs) could be worth…

Read more »

Investing Articles

A cheap FTSE 100 share that’s tipped to rebound sharply in 2025!

Recent price weakness means this FTSE share now offers stunning all-round value. I think it could experience a strong recovery…

Read more »

Light bulb with growing tree.
Investing Articles

2 sinking FTSE 100 shares I think could rebound in 2025!

Warren Buffett loves buying beaten-down stocks in anticipation of a price recovery. Here are two from the FTSE 100 that've…

Read more »

British Pennies on a Pound Note
Investing Articles

1 near-penny stock I’m buying for the last time at 19p

Our writer explains why a penny stock he bought a couple of years ago has taken a big dip since…

Read more »